Health & Bio
BeOne Beqalzi earns FDA accelerated approval for MCL; first BCL-2 inhibitor class
Sonrotoclax wins nod for relapsed/refractory mantle cell lymphoma. ORR 52%, response duration 15.8 months. Direct Venclexta challenge emerging.
Primary sources · 2